Given the increasing use of immune-checkpoint inhibitors for treating cancer, immune-related adverse events — and markers to prevent and diagnose these — are coming into focus. A systematic analysis investigates genetic, molecular, cellular and clinical risk factors of such adverse events in a large pan-cancer cohort treated with multiple agents.
This is a preview of subscription content, log in via an institution to check access.
References
Ledford, H. Nature 471, 561 (2011).
Ramos-Casals, M. et al. Nat. Rev. Dis. Primers 6, 38 (2020).
Schneider, B. J. et al. J. Clin. Oncol. 39, 4073–4126 (2021).
Haanen, J. et al. Ann. Oncol. 29, iv264–iv266 (2018).
Conroy, M. & Naidoo, J. Nat. Commun. 13, 392 (2022).
Glehr, G. et al. Front. Immunol. 13, 1011040 (2022).
Sung, C. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00572-5 (2023).
Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Nat. Rev. Immunol. 11, 519–531 (2011).
Chen, H. et al. J. Immunother. Cancer 11, e005527 (2023).
Verschueren, E. et al. Cell 182, 329–344.e319 (2020).
Nuñez, N. G. et al. Med. 4, 113–129.e117 (2023).
Das, S. & Johnson, D. B. J. Immunother. Cancer 7, 306 (2019).
Amoroso, V. et al. ESMO Open 8, 100787 (2023).
Madjar, K. et al. Front. Oncol. 13, https://doi.org/10.3389/fonc.2023.1138305 (2023).
Park, H. J. et al. Yonsei Med. J. 57, 118–126 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Rieder, D., Trajanoski, Z. Checking immunotoxicity risks of checkpoint blockade. Nat Cancer 4, 779–780 (2023). https://doi.org/10.1038/s43018-023-00561-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00561-8
- Springer Nature America, Inc.